Stock OABI OMNIAB, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News OmniAb, Inc.

Equities

OABI

US68218J1034

Market Closed - Nasdaq
Other stock markets
 16:00:02 2024-05-16 EDT 		5-day change 1st Jan Change
4.54 USD 0.00% Intraday chart for OmniAb, Inc. 0.00% -26.42%
05-09 Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M MT
05-09 OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
BU
Earnings Flash (OABI) OMNIAB Reports Q1 Revenue $3.8M, vs. Street Est of $5.9M
MT
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : OmniAb, Inc., Q1 2024 Earnings Call, May 09, 2024
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
BU
OmniAb to Participate in Five Investor Conferences in May
BU
OmniAb to Report First Quarter 2024 Financial Results on May 9
BU
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics
AQ
OmniAb : March 2024 Corporate Overview
PU
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing
MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
MT
OmniAb Swings to Q4 Loss, Revenue Declines
MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M
MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BU
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
BU
OmniAb to Participate in Two Investor Conferences in March
BU
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index
CI
OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering and Therapeutics Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OABI Stock
  4. News OmniAb, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW